Pfizer Reports Positive Phase 3 MagnetisMM‑32 Results for ELREXFIO
Pfizer Reports Positive Phase 3 MagnetisMM‑32 Results for ELREXFIO
AI-generated content · Illustrative purposes only.
Pfizer Reports Positive Phase 3 MagnetisMM‑32 Results for ELREXFIO

Pfizer has reported topline findings from the Phase 3 MagnetisMM‑32 study, showing that ELREXFIO (elranatamab) met the primary endpoint in patients with relapsed or refractory multiple myeloma after prior anti‑CD38 therapy and lenalidomide. The results demonstrated a clinically meaningful benefit in this setting, supporting ELREXFIO’s potential as ...

  • Published date: 28-10-2026 11:01 AM

Source:

Pfizer has reported topline findings from the Phase 3 MagnetisMM‑32 study, showing that ELREXFIO (elranatamab) met the primary endpoint in patients with relapsed or refractory multiple myeloma after prior anti‑CD38 therapy and lenalidomide. The results demonstrated a clinically meaningful benefit in this setting, supporting ELREXFIO’s potential as a valuable treatment option. Further details were shared in a press release aimed at healthcare professionals and investigators, reflecting ongoing progress in multiple myeloma research.

Pfizer has announced topline results from the Phase 3 MagnetisMM‑32 study evaluating ELREXFIO (elranatamab) in adults with relapsed or refractory multiple myeloma. The study met its primary endpoint, demonstrating the efficacy of ELREXFIO following prior anti‑CD38 therapy and lenalidomide treatment.

The data indicate that ELREXFIO provided a clinically meaningful benefit in this patient population, underscoring its potential role in addressing treatment needs for relapsed or refractory multiple myeloma.

This announcement was made through a company press release targeted at healthcare professionals and investigators, providing insights into the latest advancements in multiple myeloma treatment.

View Comments (0)
Want to join the conversation?
Already a member? Login New to JobsReach Healthcare? Sign up
Comments